Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

Antibody-drug conjugates (ADCs) are one of the fastest-growing oncology therapeutics,
merging the cytotoxic effect of conjugated payload with the high specific ability and …

Background Recurrent cervical cancer is a life-threatening disease, with limited treatment
options available when disease progression occurs after first-line combination therapy …

In cancer treatment, the first-generation, cytotoxic drugs, though effective against cancer
cells, also harmed healthy ones. The second-generation targeted cancer cells precisely to …

We hypothesize that different routes of administration may lead to altered pharmacokinetics/
pharmacodynamics (PK/PD) behavior of antibody-drug conjugates (ADCs) and may help to …

Simple Summary This article highlights the importance of monitoring peripheral neurotoxicity
in patients with Hodgkin lymphoma (HL) who receive brentuximab vedotin, with a particular …

A dose-escalation and expansion, phase 1/2 study (ClinicalTrials. gov, NCT04818333) was
conducted to assess the novel antibody-drug conjugate SHR-A1811 in pretreated HER2 …

Aims Chemotherapy induced peripheral neuropathy (CIPN) is a common side effect seen in
patients who have undergone most chemotherapy treatments to which there are currently no …

Abstract Design of tubulin inhibitors as anticancer drugs dynamically developed over the
past 20 years. The modern arsenal of potential tubulin-targeting anticancer agents is …

In the last decade, antibody-drug conjugates (ADCs), normally formed by a humanized
antibody and a small drug via a chemical cleavable or non-cleavable linker, have emerged …